Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Mitsubishi Tanabe to Pull Plug on Generics, Transfer Biz to Nipro in October
Mitsubishi Tanabe Pharma will pull out from the generic market as its board of directors on March 28 agreed to split off and transfer its generics and part of the long-listed product business to Nipro Corporation in October. Mitsubishi Tanabe…
To read the full story
Related Article
- Nipro Aims at 100 Billion Yen Sales for Pharma Biz by FY2020, Seeking No. 1 Spot among Research-Oriented Makers in Generic Field
October 5, 2017
- Mitsubishi Tanabe Eyes M&As for Post-Radicava Strategy in US: President
May 11, 2017
- Mitsubishi Tanabe’s Exit Shows Research-Driven Makers’ Generic Biz at Crossroads
March 31, 2017
BUSINESS
- Positive Price Revisions Seen at Several Firms in FY2026 Reform: Poll
March 6, 2026
- Japan Grants First-Ever Approval to iPSC-Based Therapies
March 6, 2026
- Meiji Starts Japan PIII Trial of Rezurock for CLAD
March 6, 2026
- Meiji Rolls Out Rezurock in Taiwan
March 6, 2026
- Toray Out-Licenses Parkinson’s Drug to Immunis
March 6, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…